Phase 3Active, not recruitingNCT06962280
Long-term tirzepatide safety in T1D with overweight or obesity
Lilly phase 3 long-term safety and efficacy trial of weekly tirzepatide versus placebo in adults with T1D and overweight or obesity.
Primary endpoints
- Change from baseline in HbA1c
Results so far
No results posted yet.